Volume 5, Issue 2

Identification of risk factors for carbamazepine‑induced serious mucocutaneous adverse reactions: A case‑control study using data from spontaneous adverse drug reaction reports

Ilma Bertulyte, Sofie Schwan, Pär Hallberg

pp. 100–138 · DOI: 10.4103/0976-500X.130051 · Published 2014

Objectives: To identify risk factors other than genetic for severe carbamazepine-induced mucocutaneous reactions, that is, SJS, TEN, and exfoliative dermatitis (ED). Materials and Methods: We did a case‑control study usi…

Assessment of demographics, treatment strategies, and evidence‑based medicine use among diabetic and non‑diabetic patients with acute coronary syndrome: A cohort study

Bhavik S. Shah, Shrikalp S. Deshpande

pp. 139–144 · DOI: 10.4103/0976-500X.130058 · Published 2014

Objectives: To evaluate and compare clinical and epidemiological characteristics, treatment strategies, and utilization of evidence-based medicine (EBM) among coronary artery disease (CAD) patients with or without diabet…

Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis

Kalpesh Jain, Mira Desai, Rajesh Solanki, Ram Kumar Dikshit

pp. 145–149 · DOI: 10.4103/0976-500X.130062 · Published 2014

Objective: To evaluate the treatment outcome of second line drugs used in directly observed treatment, short‑course (DOTS)‑Plus regimen under Revised National Tuberculosis Control Program (RNTCP). Materials and Methods: …

Folic acid supplementation on homocysteine levels in children taking antiepileptic drugs: A randomized controlled trial

Mathummal Cherumanalil Jeeja, Thayyil Jayakrishnan, Puthiya Veettil Narayanan, Mathur Sreedharan Vinod Kumar, Thayyil Thejus, Vadakay Purayil Anilakumari

pp. 93–94 · DOI: 10.4103/0976-500X.130048 · Published 2014

Objectives: To assess the level of homocysteine (tHcy) in children taking AEDs and to study whether daily oral supplementation of folic acid for 1 month will reduce the tHcy level. Materials and Methods: This was a doubl…

Informed Consent on Camera

Smita Sontakke, Parag Kinge

pp. 150–151 · DOI: 10.4103/0976-500X.130066 · Published 2014

Informed consent (IC) is one of the most important components of ethical research in human participants. Even though it is mandatory to obtain a freely given "written IC" from each study participant before he/she is enro…

Intrahepatic cholestasis in Bruton’s agammaglobulinemia receiving mesalamine for co-morbid Crohn’s disease

Giovanni Clemente Actis, Rinaldo Pellicano, Floriano Rosina

pp. 151–152 · DOI: 10.4103/0976-500X.130071 · Published 2014

The salicylate derivatives mesalamines are used to treat both ulcerative colitis and Crohn’s disease. Mesalamines are almost devoid of toxicity, apart from very low figures of nephrotoxicity as derived from large populat…

Amniotic fluid volume changes in response to frusemide induced maternal fluid shifts

K. Manikandan, S. Raghavan

pp. 153–154 · DOI: 10.4103/0976-500X.130075 · Published 2014

Frusemide use in pregnancy is generally restricted to patients with cardiac decompensation. In the past, maternal administration of oral frusemide had been tried to identify non-functioning fetal kidneys by utilizing the…

Alopecia caused by isoniazid

Ramakant Dixit, Danish Qureshi, Sunil Mathur

pp. 155–157 · DOI: 10.4103/0976-500X.130081 · Published 2014

Drug-induced alopecia is a known clinical entity and mainly seen with anti-mitotic drug therapy. Alopecia during anti-tuberculosis therapy is very uncommon and previously observed with isoniazid, thiacetazone, and ethion…

Skin rash during treatment with generic itraconazole

Antonio De Vuono, Caterina Palleria, Francesca Scicchitano, Aida Squillace, Giovambattista De Sarro, Luca Gallelli

pp. 158–160 · DOI: 10.4103/0976-500X.130086 · Published 2014

Generic drugs have the same active substance, the same pharmaceutical form, the same therapeutic indications and a similar bioequivalence with the reference medicinal product (branded). Although a similar efficacy is pos…

Tumor lysis syndrome in multiple myeloma treated with bortezomib

K. M. Dhanraj, Dubashi Biswajit

pp. 161–162 · DOI: 10.4103/0976-500X.130091 · Published 2014

A 65 year old male diagnosed as multiple myeloma was started on bortezomib developed tumor lysis syndrome. Bortezomib induced tumor lysis is rare and suitable precautions should be considered in these patients.

A case of tinnitus induced by chlorpromazine in a pediatric patient

Carla Carnovale, Paolo Pellegrino, Silvia Beretta, Gian Vincenzo Zuccotti, Valentina Perrone, Stefania Antoniazzi, Marco Pozzi, Emilio Clementi, Sonia Radice

pp. 163–165 · DOI: 10.4103/0976-500X.130110 · Published 2014

Chlorpromazine is a well‑known antipsychotic agent that binds with a variety of receptors in the central nervous system. To date, chlorpromazine has never been associated with onset of hearing disorders and tinnitus. We …

Author reply

Manish J. Barvaliya, Tejas K. Patel, C. B. Tripathi

pp. 166–167 · DOI: 10.4103/0976-500X.130116 · Published 2014

European Heart and Rhythm Association guidelines on new oral anticoagulants: A bold step forward

Vishal Sehgal, Sukhminder Jit Singh Bajwa

pp. 167–169 · DOI: 10.4103/0976-500X.130147 · Published 2014

Medical science is witnessing a progressive revolution and evolution throughout the globe with continual improvement in diagnostics and therapeutic interventions. The literary and practical updates in medical sciences ar…

Randomization and online databases for clinical trials

Jatinder Singh

pp. 173–4 · DOI: 10.4103/0976-500X.130155 · Published 2014

Lorcaserin: A novel antiobesity drug

Dick B. S. Brashier, A. K. Sharma, Navdeep Dahiya, S. K. Singh, Anjan Khadka

pp. 175–178 · DOI: 10.4103/0976-500X.130158 · Published 2014

Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts …

Why patients in pain cannot get “God’s own medicine?”

Gitanjali Batmanabane

pp. 81–2 · DOI: 10.4103/0976-500X.130040 · Published 2014

Switch over from intravenous to oral therapy: A concise overview

Jissa Maria Cyriac, Emmanuel James

pp. 83–87 · DOI: 10.4103/0976-500X.130042 · Published 2014

Majority of the patients admitted to a hospital with severe infections are initially started with intravenous medications. Short intravenous course of therapy for 2-3 days followed by oral medications for the remainder o…

Off‑label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities

Sandeep Kumar Gupta, Roopa Prasad Nayak

pp. 88–92 · DOI: 10.4103/0976-500X.130046 · Published 2014

Off-label prescribing of medicines is prevalent worldwide because it gives freedom to physicians to apply new therapeutic options based on the latest evidence. Although physicians may lawfully prescribe approved drugs fo…